We are creating medicines to cure multiple cancers. This not only provides solutions to patients but to failed biotech industry assets that need a new mechanism to be effective. We have an experienced management team that can move our products through development to revenue. We are a preclinical drug development company that is capital efficient and can move quickly to create value for our investors.